The Amniox Advantage campaign explores Amniox’s platform technology that has set the standard in successfully treating complex and non-healing wounds
Miami, FL – June 10, 2021 – Amniox Medical, Inc. (Amniox), a TissueTech, Inc. company and pioneer in the clinical application of human birth tissue products, is launching a new awareness campaign that showcases the Amniox comprehensive family of human birth tissue-based products to facilitate wound healing and reduce associated cost of care. This year, Amniox commemorates ten years of improving patients’ lives by offering the natural potential of birth tissue products for surgical and wound applications to help expedite functional recovery.
The campaign – The Amniox Advantage – features evidence-based best practices while exploring the economic impact on our healthcare delivery system resulting from treating complex wounds. In one study published by the Alliance of Wound Care Stakeholders, researchers found that chronic non-healing wounds impact nearly 15% of Medicare beneficiaries (8.2 million) with an estimated annual cost is $28 billion.1
“We are proud to support all of the members of the American Board of Wound Management and acknowledge all that they do to promote wound care – especially during Wound Healing Awareness Month,” said Herbert Slade, MD, Chief Medical Officer, TissueTech, Inc. “For ten years now, Amniox has been recognized as a leader in complex wound management through our clinical research and medical contributions. As such, we applaud the education efforts of the Board.”
Amniox is committed to addressing unmet patient clinical needs, as illustrated in a clinical case study using NEOX® CORD 1K as an adjunct therapy to treat necrotizing fasciitis, a severe infection often involving the foot and ankle. This type of infection carries very high morbidity and mortality rate, frequently resulting in amputation. In honor of Wound Care Awareness Month, Amniox has supplemented its website to showcase the Amniox Advantage campaign.
About Amniox Medical, Inc.
Amniox Medical, Inc. is a TissueTech, Inc. company. It is focused on harnessing the unique power of human birth tissue to support regenerative healing and functional recovery in surgical, chronic wound, and musculoskeletal applications. The Amniox family of cryopreserved amniotic membrane and umbilical cord products are processed using its proprietary CRYOTEK® technology to retain the birth tissue’s structural and functional integrity. Amniox is committed to facilitating optimal clinical outcomes, solving previously unmet clinical and patient needs, and positively impacting patients’ lives. Connect with Amniox on our Website, Physician Portal, Facebook, LinkedIn, Instagram, and Twitter, or through your local sales professional.
About TissueTech, Inc.
TissueTech, Inc. is an emerging biotechnology company and leader in regenerative medicine using human birth tissue. TissueTech’s pioneering amniotic membrane and umbilical cord products are processed using its proprietary CRYOTEK® cryopreservation technology, designed to retain the tissue’s structural and functional integrity. Today, TissueTech is breaking new ground with multiple Investigational New Drug clinical trials underway as the company pursues 351 biologics approval for products to treat patients’ unmet clinical needs. TissueTech is committed to empowering healthcare professionals with solutions to deliver optimal patient outcomes by fostering innovation through evidence-based science. Since its inception, clinicians have performed over 600,000 human implants with the company’s products and published over 380 peer-reviewed studies supporting TissueTech’s platform technology. Learn more at https://tissuetech.com.